Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERE-120 in idiopathic Parkinson's disease
NCT00400634Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Nov 2006
- Primary completion
- Nov 2008
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Neurturin gene therapy in Parkinson's disease (PD), sponsored by Sangamo Therapeutics. Started Nov 2006; status: completed.
02
Drugs
Neurturin gene therapy
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00400634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400634.